Management of chronic obstructive pulmonary disease: An emphasis on recently approved medications and products in the pipeline; Focus On Boceprevir: A new oral protease inhibitor for the treatment of chronic hepatitis C
New Heart Failure Med Will be Priced 'Competitively'
Inpefa (sotagliflozin) is in the SGLT inhibitor class recommended as first-line treatment for heart failure by the American Heart Association and other groups. Jardiance (empaglifozin), a competitor in that class, has a list price of $570.48 for a month's supply.
Drug Manufacturer Coupons: Marketing Tools Perceived as Charitable Assistance
The frequency of drug manufacturer coupon utilization is associated with more market competition—but not patients’ out-of-pocket costs.
FDA Clears Paxlovid as First Oral Antiviral for COVID-19
More than 11.6 million treatment courses of the medication have been prescribed in the U.S. to date.
Unique New Lymphoma Treatment Priced at $37,500 Monthly
AbbVie and Genmab have set a price for newly approved Epkinly epcoritamab-bysp).
FDA Approves New Treatments for Opioid Overdose, Opioid Use Disorder
The FDA recently approved Brixadi to treat moderate to severe opioid use disorder in patients who have already started treatment with a transmucosal form of buprenorphine, and have approved Opvee as an emergency treatment to reverse known or suspected opioid overdose in people ages 12 years and older.
First Interchangeable Biosimilar to Humira Gets Approval for Pen Form
The Cyltezo Pen is scheduled to be on the market and available on July 1.
2 Clarke Drive Cranbury, NJ 08512